Under the auspices of this commercial license, Generex has established a branch office in exclusive Dubai Healthcare City operating as ‘Generex Biotechnology Corporation Mena’ (Middle East and North Africa).
Generex, through this branch office, will work closely with the regulatory and marketing personnel of Leosons General Trading Company, the company’s licensee in the region for the registration, importation, marketing, distribution, and sale of Generex Oral-lyn, the company’s proprietary oral insulin spray product.
William Abajian, senior executive advisor, global strategic alliances & business development, Generex, said: “This augmented presence in the region will assist Generex to bring Generex Oral-lyn and its new paradigm for the treatment of diabetes to the more than 15 million patients with diabetes in the region.”